[2,6-dichloro-3-(trifluoromethyl)phenyl]methanamine | 1092461-13-6

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: [2,6-dichloro-3-(trifluoromethyl)phenyl]methanamine
• 英文别名: 2,6-Dichloro-3-(trifluoromethyl)benzylamine
• CAS: 1092461-13-6
• 化学式: C₈H₆Cl₂F₃N
• mdl: MFCD11519352
• 分子量: 244.044
• InChiKey: NDXOPDUEXPJASP-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.9
• 重原子数：
  14
• 可旋转键数：
  1
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.25
• 拓扑面积：
  26
• 氢给体数：
  1
• 氢受体数：
  4

反应信息

• 作为反应物：
  描述：

  [2,6-dichloro-3-(trifluoromethyl)phenyl]methanamine 在 ammonium hydroxide 、 氧气 作用下， 以 2-甲基-2-丁醇 为溶剂， 110.0 ℃ 、300.01 kPa 条件下， 反应 24.0h， 以95%的产率得到2,6-二氯-3-(三氟甲基)苯腈
  参考文献：
  名称：

  “ Nanorust”催化的胺的良性氧化，用于腈的选择性合成

  摘要：

  有机腈构成有机合成中的关键前体和中心中间体。另外，腈是在许多医学和生物学上重要的化合物中发现的通用基序。通常，这些腈是使用有毒氰化物通过传统的氰化步骤合成的。本文中，我们报道了使用可重复使用的基于“纳米锈”（纳米级Fe 2 O 3）的分子氧催化剂，伯胺选择性和环境无害的氧化转化，用于合成结构多样的芳香族，脂肪族和杂环腈。

  DOI：

  10.1002/cssc.201402613

文献信息

• Adenine derivatives as protein kinase inhibitors
  申请人：B.C.I. PHARMA

  公开号：US11236093B2

  公开（公告）日：2022-02-01

  The present invention relates to a compound suitable for use as a kinase inhibitor according to general formula (I) [compound (C), herein after], or the N-oxide, pharmaceutically acceptable salt, pharmaceutically acceptable solvate, or stereoisomer thereof, formula (I) wherein A, R1, R2, R3, R3′, R4, R4′, X, Y, Z, T are as defined in the claims. The invention further relates to an in vitro method of inhibiting protein kinase activity which comprises contacting a protein kinase with a compound of formula (I), or the N-oxide, pharmaceutically acceptable salt, pharmaceutically acceptable solvate, or stereoisomer thereof. The invention further relates to the compounds of formula (I) per se, as well as to their use as a medicament, and for use or in a method of treatment of a disease mediated by a protein kinase selected from cancer, inflammatory disorders, cardiovascular diseases, viral induced diseases, circulatory diseases, fibro-proliferative diseases and pain sensitization disorders.

  本发明涉及根据通式(Ⅰ)[化合物(C)，以下同]的适于用作激酶抑制剂的化合物，或其N-氧化物、药学上可接受的盐、药学上可接受的溶液或立体异构体，式(Ⅰ)其中A、R1、R2、R3、R3′、R4、R4′、X、Y、Z、T如权利要求书中所定义。本发明进一步涉及一种抑制蛋白激酶活性的体外方法，该方法包括使蛋白激酶与式(I)化合物或其N-氧化物、药学上可接受的盐、药学上可接受的溶液或立体异构体接触。本发明进一步涉及式（I）化合物本身及其作为药物的用途，以及用于治疗由蛋白激酶介导的选自癌症、炎症性疾病、心血管疾病、病毒引起的疾病、循环系统疾病、纤维增生性疾病和痛觉过敏性疾病的方法。
• ADENINE DERIVATIVES AS PROTEIN KINASE INHIBITORS
  申请人：B.C.I. PHARMA

  公开号：US20190127379A1

  公开（公告）日：2019-05-02

  The present invention relates to a compound suitable for use as a kinase inhibitor according to general formula (I) [compound (C), herein after], or the N-oxide, pharmaceutically acceptable salt, pharmaceutically acceptable solvate, or stereoisomer thereof, formula (I) wherein A, R 1 , R 2 , R 3 , R 3′ , R 4 , R 4′ , X, Y, Z, T are as defined in the claims. The invention further relates to an in vitro method of inhibiting protein kinase activity which comprises contacting a protein kinase with a compound of formula (I), or the N-oxide, pharmaceutically acceptable salt, pharmaceutically acceptable solvate, or stereoisomer thereof. The invention further relates to the compounds of formula (I) per se, as well as to their use as a medicament, and for use or in a method of treatment of a disease mediated by a protein kinase selected from cancer, inflammatory disorders, cardiovascular diseases, viral induced diseases, circulatory diseases, fibro-proliferative diseases and pain sensitization disorders.